Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes reviewing medical history, performing physical examinations, and conducting necessary laboratory tests.

The purpose of this assessment is to ensure that the patient meets all the criteria required to participate in the trial.

The patient begins the induction chemotherapy phase, which consists of six cycles of treatment. This phase aims to achieve a complete response in patients with peripheral T-cell lymphoma.

Medications administered during this phase include etoposide, methylprednisolone hemisuccinate, prednisone, brentuximab vedotin, doxorubicin hydrochloride, vincristine sulfate, and cyclophosphamide monohydrate. These are given through intravenous infusion or oral use, depending on the specific medication.

After completing the induction chemotherapy, the patient’s response to the treatment is evaluated using imaging techniques such as PET-CT or CT scans.

The evaluation determines whether the patient has achieved a complete response, which is necessary to proceed to the next stage of the trial.

If a complete response is achieved, the patient undergoes autologous stem cell transplantation. This procedure involves collecting the patient’s own stem cells, which are then reintroduced into the body after intensive chemotherapy.

The goal of this transplantation is to prolong progression-free survival, which means extending the time during which the disease does not worsen.

After the transplantation, the patient enters a follow-up phase where regular monitoring is conducted to assess overall health and detect any signs of disease progression.

This phase includes routine medical check-ups, imaging tests, and laboratory assessments to ensure the patient’s well-being and to evaluate the long-term effects of the treatment.